Youngy Health(SZ:300247) Xin Lang Cai Jing·2025-08-27 02:42Core Insights - Rongjie Health (300247.SZ) reported a total operating revenue of 433 million yuan for the first half of 2025, an increase of 99.38 million yuan compared to the same period last year, marking a 29.81% year-on-year growth [1] - The net profit attributable to shareholders reached 47.52 million yuan, up by 18.84 million yuan from the same period last year, reflecting a 65.72% year-on-year increase [1] - The net cash inflow from operating activities was 65.05 million yuan, an increase of 25.14 million yuan year-on-year, representing a 62.99% growth [1] Financial Performance - The latest debt-to-asset ratio stands at 17.34% [3] - The gross profit margin is 35.81%, up by 1.79 percentage points from the previous quarter and 3.82 percentage points year-on-year [3] - Return on equity (ROE) is 4.27%, an increase of 1.53 percentage points compared to the same period last year [3] - The diluted earnings per share (EPS) is 0.06 yuan, an increase of 0.02 yuan year-on-year, reflecting a 65.55% growth [3] - The total asset turnover ratio is 0.31 times, up by 0.04 times year-on-year, representing a 16.59% increase [3] - The inventory turnover ratio is 1.53 times [3] Shareholder Structure - The number of shareholders is 32,000, with the top ten shareholders holding 220 million shares, accounting for 27.34% of the total share capital [3] - The largest shareholder is Rongjie Investment Holding Group Co., Ltd., holding 14.54% of the shares [3]